1. Korea
In a 2016 Published Study, Ye-Kyu Park and Choong-Hak Park showed promise in their trial.
Department of Obstetrics and Gynecology, Dankook University College of Medicine, Cheonan, Korea.
Choong-Hak Park. Department of Obstetrics and Gynecology, Dankook University College of Medicine, 119 Dandae-ro, Dongnam-gu, Cheonan 31116, Korea. Tel: +82-41-550-3941, Fax: +82-41-555-6335, rk.ca.kooknad@01hcp
"Conclusion: Our data showed that CR rate was fantastic in CIN group (95%). This study suggests that PDT can be recommended as new optimistic management modality on the patients with pre-malignant CIN lesions including carcinoma in situ and relatively early invasive cancer of the uterine cervix. Combined chemo-photodynamic therapy is essential in case of invasive cervical cancer. For the young age group who desperately want to preserve their fertility and have a healthy baby, PDT can be a beacon of hope."
Source: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5120067/
2. Moscow, Russia
The only practicing doctor I have found who offers patient treatments for cervical dysplasia is Dr. Maxim Afanasev who treats patients in Moscow. While shares many positive testimonials on his Instagram page, I have yet to find any external mention of his claims.I did find a Russian study which had 90%+ success rates in treating cervical dysplasia caused by HPV infections using photodynamic therapy.
3. Mexico
Dr. Eva Ramón Gallegos has used photodynamic therapy to treat Mexican women with HPV and cervical dysplasia lesions. Her research has led to the eradication of HPV in 100% of the HPV positive patients without precancerous lesions, 64.3% of patients with HPV and precancerous lesions, and 57.2% of patients without HPV, but with precancerous lesions.Source: https://www.eluniversal.com.mx/english/mexican-scientist-cures-human-papilloma-virus
4. Brazil
Researchers in Brazil showed long-term effectiveness in using photodynamic therapy for CIN treatment."Results: 75% (n = 42) of CIN 1 patients presented a complete response to PDT and only 23.2% (n = 13) of recurrence, progression, and/or lesions remaining two years after PDT.
For CIN 2/3 patients, 90% were observed to be cured after one and two years of follow up. (4) Conclusions: PDT presented best results two years after a non-invasive, fast, and low-cost procedure and in comparison with the placebo group, preventing the progression of cervical intraepithelial neoplasia and preserving the cervix."
Source: https://www.ncbi.nlm.nih.gov/pubmed/31336848
The product has been in development for many years. Clinical trials have moved along successfully, and in July 2019 a partnership was reached with Chinese biotechnology company Asieris to manufacture and distribute the device. A final round of clinical trials is scheduled to be completed in China. As soon as 2022, the product could be available in key markets: Asia, Europe and the US.
Source: https://www.ncbi.nlm.nih.gov/pubmed/31336848
5. Norway
In perhaps the most promising instance of photodynamic therapy used to treat cervical dysplasia, Norwegian pharmaceutical company Photocure ASA has developed an intravaginal device called Cevira® that delivers one two doses of a proprietary drug directly to the cervix. The device is inserted by the gynecologist and is later removed by the patient. There is no downtime for the treatment and patients can go about their day as normal. It is a completely non-surgical treatment that preserves the cervical anatomy and function.The product has been in development for many years. Clinical trials have moved along successfully, and in July 2019 a partnership was reached with Chinese biotechnology company Asieris to manufacture and distribute the device. A final round of clinical trials is scheduled to be completed in China. As soon as 2022, the product could be available in key markets: Asia, Europe and the US.
No comments:
Post a Comment